Deep Brain Stimulation for Freezing of Gait
(CnF-DBS-FOG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this trial is to study the safety, practicality, and effectiveness of deep brain stimulation (DBS) therapy in a brain region called the cuneiform nucleus (CnF) to treat disabling freezing of gait (FOG) in patients with Parkinson's disease (PD) when standard treatments are no longer effective. The study uses either the Medtronic's Percept™ PC or RC systems for DBS therapy. Please note that although the Medtronic systems are FDA-approved for other diseases, they have not been approved for the treatment of FOG in PD and their use for stimulation of the CnF target is experimental.
Are You a Good Fit for This Trial?
This trial is for people with Parkinson's disease who have severe freezing of gait that does not improve with standard medications like levodopa. Participants should be adults and able to undergo surgery, but specific inclusion or exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Deep Brain Stimulation (DBS) of Cuneiform Nucleus (CnF)
Trial Overview
The study tests deep brain stimulation (DBS) in a part of the brain called the cuneiform nucleus using Medtronic devices. Some participants will get active DBS, while others receive no stimulation (sham). The goal is to see if DBS helps reduce freezing of gait.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Iahn Cajigas
Lead Sponsor
University of Miami
Collaborator
University of California, San Francisco
Collaborator
Michael J. Fox Foundation for Parkinson's Research
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.